Translate this page into:
Dexamethasome-cyclophosphamide pulse therapy for systemic sclerosis
Correspondence Address:
Ramji Gupta
M-54, Jal Vihar Road, Lajpat Nagar-II, New Delhi - 110054
India
| How to cite this article: Gupta R. Dexamethasome-cyclophosphamide pulse therapy for systemic sclerosis. Indian J Dermatol Venereol Leprol 2009;75:511 |
Sir,
This is in reference to the article ′Therapeutic trials for systemic sclerosis: An update′ by Sardana and Garg . [1] The comprehensive review needs the following references [2],[3],[4],[5],[6],[7],[8] to be added.
It may also be added that as many as 14 dermatologists in various institutions have used dexamethasone cyclophosphamide pulse therapy (DCP)/dexamethasone pulse therapy (DP) regimen for about 300 systemic sclerosis patients [8] and found satisfactory recoveries. DCP therapy consists of transfusing 100 mg dexamethasone dissolved in 500 ml 5% glucose over one to two hours, for three consecutive days every month, along with cyclophosphamide 500 mg on day one in the same drip and 50 mg daily, orally, in between the pulses. In DP only dexamethasone 100 mg is transfused in 500 ml 5% glucose over one to two hours for three consecutive days every month. It is used in those patients where cyclophosphamide is contraindicated.
For the information of the dermatologists, DCP / DC is able to bring about a total/almost total reversal of the changes, including skin hardening, pigmentary changes, arthritis, dysphagia, dyspnea to a variable extent, gangrene, fingertip ulceration, and even Raynand′s phenomenon, which are commonly observed in progressive systemic sclerosis patients. The total treatment is to be given for three to four years. Less doses as used by those who have found unsatisfactory results, are obviously due to inadequate treatment.[9]
| 1. |
Sardana K, Garg VK. Therapeutic trials for systemic sclerosis: An update. Indian J Dermatol Venerol Leprol 2008;74:436-46.
[Google Scholar]
|
| 2. |
Pasricha JS, Ramam M, Shah S. Reversal of systemic sclerosis with dexamethasone pulses. Indian J Dermatol Venereol Leprol 1990; 56: 40-42.
[Google Scholar]
|
| 3. |
Pai BS, Srinivas CR, Sabitha L, Shenoi SD, Balachandran CN, Acharya S. Efficacy of dexamethasone pulse therapy in progressive systemic sclerosis. Int J Dermatol 1995;34:726-8.
[Google Scholar]
|
| 4. |
Vatwani V, Palta SC, Verma N, Pathak PR, Singh RP. Pulse therapy in scleroderma. Indian Pediatr 1994;31:993-5.
[Google Scholar]
|
| 5. |
Dalal M, Balachandran C, Sabitha L. Monthly dexamethasone pulse therapy in systemic sclerosis. A clinic evaluation. Abstract 27 th IADVL Conference 1999. p. 87.
[Google Scholar]
|
| 6. |
Sharda B, Kumar A, Kakker R, Adya CM, Pande I, Uppal SS, et al Intravenous dexamethasone pulse therapy in diffuse systemic sclerosis: A randomized placebo controlled study. Rheumatol Int 1994;14:91-4.
[Google Scholar]
|
| 7. |
Khaitan BK, Gupta S. Systemic sclerosis successfully treated with dexamethasone pulse therapy. Dermascan 1999;1:9-11.
[Google Scholar]
|
| 8. |
Gupta R. Systemic sclerosis treated with dexamethasone pulse therapy. Indian J Dermatol Venereol Leprol 2003;69:191-2.
[Google Scholar]
|
| 9. |
Ramam M, Bhat R. Pulse therapy in other diseases. In: Pasricha JS editor. Pulse therapy in pemphigus and other diseases. 3 rd ed. New Delhi: Mehta Publishers; 2006. p. 91-5.
[Google Scholar]
|
Fulltext Views
1,307
PDF downloads
776
